Cost-utility analysis of dorzagliatin combined with metformin in the treatment of type 2 diabetes mellitus patients with poor glycemic control with metformin / 中国药房
China Pharmacy
; (12): 724-728, 2024.
Article
in Zh
| WPRIM
| ID: wpr-1013109
Responsible library:
WPRO
ABSTRACT
OBJECTIVE To assess the long-term cost-effectiveness of five glucagon-like peptide-1 receptor agonists (GLP- 1RAs) in the treatment of poorly controlled type 2 diabetes mellitus (T2DM) treated with metformin. METHODS Baseline data from patients in previously published meta-analysis and included randomized controlled trials (RCTs) were extracted to predict survival, long-term efficacy, and costs for each group using the United Kingdom prospective diabetes study outcome model 2.1. The cost-effectiveness of 5 GLP-1RAs (liraglutide, lixisenatide, exenatide, dulaglutide, and semaglutide) was analyzed by cost- utility analysis. Sensitivity analysis and scenario analysis were also performed to verify the uncertainty of basic analysis results. RESULTS A total of 21 RCTs with 6 796 patients were included. Survival analysis curves showed the superiority of semaglutide in reducing the risk of death from cardiovascular disease and dulaglutide in reducing the risk of all-cause mortality over other GLP- 1RAs. The cost-utility analysis showed that the five drugs were economically superior to inferior in the order of lixisenatide, semaglutide, exenatide, dulaglutide, and liraglutide; one-way and probabilistic sensitivity analyses indicated that the results were robust. The scenario analysis results indicated that the price of semaglutide should decrease by at least 54.64% to 369.21 yuan, which is cost-effectiveness compared to lixisenatide. CONCLUSIONS For T2DM patients in China with poor glycemic control after treatment with metformin, lixisenatide and semaglutide may be considered as the preferred regimen.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
China Pharmacy
Year:
2024
Type:
Article